Health Canada Accepts Seattle Genetics' (SGEN) ADCETRIS NDS for REview
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Join SI Premium – FREE
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the validation period is complete and Health Canada has accepted for review its New Drug Submission (NDS) for the use of ADCETRIS (brentuximab vedotin) in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). The NDS will be reviewed under the Health Canada policy of Notice of Compliance with Conditions (NOC/c). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in Hodgkin lymphoma and sALCL.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Nuvectis Pharma (NVCT) files $200M mixed shelf
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
